Pregnancy monitoring mothers

The type of interface is largely determined by who is going to use it and for what piupose. Therefore, the fifth design dimension is the decision of who the system is for. In the case of pregnancy monitoring, the system is used by both caregivers and parents, especially the mother to be. Moreover, the interface between the user and the system also includes the wearable itself, as it is in direct contact with the skin of the future mother. 

Hypertension can develop rapidly during the third trimester of pregnancy. Untreated, it can pose a danger to both mother and child. So-called gestational hypertension commonly disappears after pregnancy but not always. And if your blood pressure was elevated prior to pregnancy it s particularly important to monitor it on a regular basis. 

Neonates require close monitoring if their mothers received enzyme inducers such as phenytoin, pheno-barbital, carbamazepine, or rifampin during pregnancy... 

Neonates require close monitoring if their mothers received enzyme inducers such as phenytoin, phenobar-bital, carbamazepine, or rifampin during pregnancy or if they need one of these drugs themselves. Examples of drugs that inhibit the metabolism of other medications include cimetidine, erythromycin, and ketoconazole." ... 

Given the current information, it is advisable to limit use of blue cohosh in pregnancy only under the supervision of a practitioner who is familiar with its use and who can appropriately monitor both the mother and infant for possible adverse effects. Also see Adverse Events and Side Effects and Pharmacological Considerations for this entry. 

Pregnancy is a whole new experience, especially for women having their first child. It is accompanied by uncertainty, body changes, and even pain. Therefore, they do not want to be troubled by additional nuances of monitoring systems. Ideally, accurate monitoring and timely identification of possible complications have to be provided, whilst ensuring the comfort of the mother. What are the most important aspects to... 

This paper provides fee foundation for our sleeping/wak-ing states approach to assessment of infant functional outcome as it relates to DHA status of fee infant or fee mother during pregnancy. The history of our methodology for assessing sleep and wake states and comparisons with the approaches of others have been published (1,10) The instrument that we use, the Motility Monitoring System (MMS), is described in detail herein. In addition, we provide a summary of recently published data of sleep and wake states vs. DHA status (2) and the results of sleep-wake data for infants born to women with and without gestational diabetes melli-tus (GDM). 

---